Cytomed Therapeutics LTD (GDTC) — SEC Filings

Overview

Cytomed Therapeutics LTD (GDTC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 31, 2026: CytoMed Therapeutics Ltd filed a Form 6-K on March 31, 2026, reporting as a foreign issuer. The filing includes the standard 6-K report document and a complete submission text file. The company's mailing and business address is listed as ONE COMMONWEALTH, 1 COMMONWEALTH LANE, U0 149544.

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 2 bullish, 28 neutral, 1 mixed. The dominant filing sentiment for Cytomed Therapeutics LTD is neutral.

Filing Type Overview

Cytomed Therapeutics LTD (GDTC) has filed 26 6-K, 3 20-F, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

• 6-K Filing — 6-K · Apr 14, 2026
• CytoMed Therapeutics Files 6-K Report — 6-K · Mar 31, 2026 Risk: low
  CytoMed Therapeutics Ltd filed a Form 6-K on March 31, 2026, reporting as a foreign issuer. The filing includes the standard 6-K report document and a complete
• CytoMed Advances Cell Therapies, Faces Regulatory Hurdles — 20-F · Mar 31, 2026 Risk: high
  CytoMed Therapeutics Ltd (GDTC) filed its 20-F for the fiscal year ended December 31, 2025, indicating its status as an emerging growth company. The company rep
• CytoMed Therapeutics to Explore Phase I Trial with Universiti Malaya — 6-K · Dec 8, 2025 Risk: medium
  On December 8, 2025, CytoMed Therapeutics Limited announced it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre. This collaboratio
• CytoMed Acquires TC BioPharm Assets for Cancer Treatment — 6-K · Nov 18, 2025 Risk: medium
  On November 18, 2025, CytoMed Therapeutics Limited announced the completion of its acquisition of synergistic assets from TC BioPharm Limited. These assets are
• 6-K Filing — 6-K · Nov 6, 2025
• CytoMed Chairman Buys More Shares — 6-K · Oct 22, 2025 Risk: low
  On October 22, 2025, CytoMed Therapeutics Limited announced that its Executive Chairman and substantial shareholder, Mr. Choo Chee Kong, increased his stake in
• CytoMed Therapeutics Bids for TC BioPharm Assets — 6-K · Oct 14, 2025 Risk: medium
  On October 14, 2025, CytoMed Therapeutics Limited announced it has submitted an undisclosed cash bid for potentially synergistic assets of TC BioPharm Limited (
• CytoMed Therapeutics AML Research Published — 6-K · Oct 2, 2025 Risk: medium
  On October 2, 2025, CytoMed Therapeutics Limited announced a publication detailing collaborative research with The University of Texas, MD Anderson Cancer Cente
• CytoMed Therapeutics Files 6-K for Period Ending 06/30/2025 — 6-K · Sep 30, 2025 Risk: low
  CytoMed Therapeutics Limited, formerly CytoMed Therapeutics Pte. Ltd., filed a Form 6-K report for the financial period ended June 30, 2025. The company, incorp
• CytoMed Expands NK Cell Production, Plans New Cord Blood Biotech — 6-K · Aug 28, 2025 Risk: medium
  On August 28, 2025, CytoMed Therapeutics Limited announced its expansion into clinical-scale natural killer (NK) cell production derived from cord blood, in add
• CytoMed Therapeutics Signs At-the-Market Sales Agreement — 6-K · Aug 19, 2025 Risk: medium
  On August 18, 2025, CytoMed Therapeutics Limited entered into an at-the-market sales agreement with R.F. Lafferty & Co., Inc. as sales agent. This agreement all
• CytoMed Therapeutics Issues Press Release — 6-K · Jul 21, 2025 Risk: low
  On July 21, 2025, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details about the content of this
• CytoMed Therapeutics Holds Annual Shareholders Meeting — 6-K · Jul 3, 2025 Risk: low
  CytoMed Therapeutics Limited filed a Form 6-K on July 3, 2025, reporting on events for the month of July 2025. The filing indicates that the company held its An
• CytoMed Therapeutics Files 6-K for Annual Shareholder Meeting — 6-K · May 16, 2025 Risk: low
  CytoMed Therapeutics Limited filed a Form 6-K on May 16, 2025, to report information related to its upcoming annual general meeting of shareholders. The filing
• CytoMed Therapeutics Ltd Files 20-F for FY2024 — 20-F · Apr 28, 2025 Risk: low
  CytoMed Therapeutics Ltd filed its 20-F report for the fiscal year ending December 31, 2024. The company, previously known as CytoMed Therapeutics Pte. Ltd. unt
• CytoMed Therapeutics Ltd. Files January 2025 6-K Report — 6-K · Jan 6, 2025 Risk: low
  On January 6, 2025, CytoMed Therapeutics Limited announced its financial results for the period ending December 31, 2024. The company, formerly known as CytoMed
• CytoMed Therapeutics Reports Rise in Collaborations — 6-K · Dec 5, 2024 Risk: low
  CytoMed Therapeutics Limited, formerly CytoMed Therapeutics Pte. Ltd., filed a Form 6-K on December 5, 2024. The company, incorporated in Singapore with its pri
• CytoMed Therapeutics Ltd. Files Form 6-K — 6-K · Nov 20, 2024 Risk: low
  On November 20, 2024, CytoMed Therapeutics Limited issued a press release. The company's former name was CytoMed Therapeutics Pte. Ltd., with a name change occu
• CytoMed Therapeutics Announces Press Release — 6-K · Oct 7, 2024 Risk: low
  On October 7, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details about the content of thi
• CytoMed Therapeutics Issues Press Release — 6-K · Oct 3, 2024 Risk: low
  On October 3, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of
• CytoMed Therapeutics Files 6-K for June 30, 2024 Period — 6-K · Sep 30, 2024 Risk: low
  CytoMed Therapeutics Limited filed a Form 6-K on September 30, 2024, reporting for the financial period ended June 30, 2024. The company, previously known as Cy
• CytoMed Therapeutics Announces Board Re-organization — 6-K · Jun 20, 2024 Risk: low
  CytoMed Therapeutics Ltd. filed a Form 6-K on June 20, 2024, reporting a board re-organization. This action is in accordance with Regulation 117 of the Company'
• CytoMed Therapeutics Holds Annual Shareholders Meeting — 6-K · May 24, 2024 Risk: low
  CytoMed Therapeutics Limited held its Annual Shareholders Meeting on May 15, 2024, at 11:00 a.m. local time. The company is a foreign private issuer filing a Fo
• SC 13G/A Filing — SC 13G/A · May 23, 2024
• CytoMed Therapeutics Files 6-K for Proxy Statement — 6-K · Apr 24, 2024 Risk: low
  CytoMed Therapeutics Limited filed a Form 6-K on April 24, 2024, to provide its proxy statement and notice of an annual general meeting. The company, incorporat
• CytoMed Therapeutics Ltd Files 20-F for Fiscal Year Ended December 31, 2023 — 20-F · Apr 22, 2024 Risk: low
  CytoMed Therapeutics Ltd (GDTC) filed a Foreign Annual Report (20-F) with the SEC on April 22, 2024. CytoMed Therapeutics Ltd filed its annual report on Form 20
• CytoMed Therapeutics Issues Press Release — 6-K · Mar 18, 2024 Risk: low
  On March 18, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of
• CytoMed Therapeutics Issues March 4 Press Release — 6-K · Mar 4, 2024 Risk: low
  On March 4, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of t
• SC 13G Filing — SC 13G · Feb 14, 2024
• CytoMed Secures Malaysian Patent for Cancer-Targeting T-Cell Tech — 6-K · Jan 29, 2024
  CytoMed Therapeutics Ltd. announced on January 29, 2024, that the Intellectual Property Corporation of Malaysia granted a patent (Application No.: PI2019004561,

Risk Profile

Risk Assessment: Of GDTC's 26 recent filings, 1 were flagged as high-risk, 6 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Choo Chee Kong
• Mr Choo Chee Kong

Industry Context

CytoMed Therapeutics operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on cell and gene therapies for cancer. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Key trends include advancements in immunotherapy, personalized medicine, and the increasing use of AI in drug discovery and clinical trial design.

Top Tags

press-release (6) · foreign-private-issuer (6) · filing-update (5) · reporting (4) · shareholder-meeting (3) · collaboration (2) · biotech (2) · acquisition (2) · oncology (2) · cell-therapy (2)

Key Numbers

• Ordinary Shares Outstanding: 11,828,435 — As of December 31, 2025, indicating the current share count for investors.
• Fiscal Year End: 2025 — The period covered by this annual report, providing the latest financial and operational snapshot.
• Filing Date: 2026-03-31 — The date the 20-F was filed, indicating the recency of the disclosed information.
• Company Incorporation Date: 2018-03-09 — CytoMed Therapeutics Limited was incorporated in Singapore, showing its operational history.
• BRCA Agreement Date: 2024-12-30 — Date of the Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited, highlighting a recent strategic partnership.
• Clinical Study Agreement Date: 2023-03-10 — Date of the Investigator-Initiated Clinical Study Agreement with National University Hospital Singapore, indicating ongoing research efforts.
• Shares Purchased: 105,824 — By Executive Chairman Mr. Choo Chee Kong
• Financial Period End: 06/30/2025 — The report covers the period ending on this date.
• SEC File Number: 001-41677 — Unique identifier for the company's filings with the SEC.
• Name Change Date: 2021-07-16 — Effective date of the company's name change.

Frequently Asked Questions